Entity

Time filter

Source Type

Saitama, Japan

Matsui I.,Japan National Institute of Advanced Industrial Science and Technology | Urushibata Y.,Japan National Institute of Advanced Industrial Science and Technology | Urushibata Y.,NB Health Laboratory Co. | Shen Y.,Japan National Institute of Advanced Industrial Science and Technology | And 3 more authors.
FEBS Letters | Year: 2011

Archaea-specific D-family DNA polymerase forms a heterotetramer consisting of two large polymerase subunits and two small exonuclease subunits. The N-terminal (1-300) domain structure of the large subunit was determined by X-ray crystallography, although ∼50 N-terminal residues were disordered. The determined structure consists of nine alpha helices and three beta strands. We also identified the DNA-binding ability of the domain by SPR measurement. The N-terminal (1-100) region plays crucial roles in the folding of the large subunit dimer by connecting the ∼50 N-terminal residues with their own catalytic region (792-1163). Structured summary: DP2 binds to DP2 by molecular sieving (View interaction) DP2 binds to DP2 by fluorescence technology (View interaction) DP2 binds to DP2 by circular dichroism (View interaction) © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. Source


Yamasaki K.,Japan National Institute of Advanced Industrial Science and Technology | Yamasaki K.,NB Health Laboratory Co. | Urushibata Y.,Japan National Institute of Advanced Industrial Science and Technology | Yamasaki T.,Japan National Institute of Advanced Industrial Science and Technology | And 2 more authors.
FEBS Letters | Year: 2010

Archaea-specific D-family DNA polymerase forms a heterotetramer consisting of two large polymerase subunits and two small exonuclease subunits. We analyzed the structure of the N-terminal 200 amino-acid regulatory region of the small subunit by NMR and revealed that the N-terminal ∼70 amino-acid region is folded. The structure consists of a four-α-helix bundle including a short parallel β-sheet, which is similar to the N-terminal regions of the B subunits of human DNA polymerases α and ε, establishing evolutionary relationships among these archaeal and eukaryotic polymerases. We observed monomer-dimer equilibrium of this domain, which may be related to holoenzyme architecture and/or functional regulation. © 2010 Federation of European Biochemical Societies. Source


An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.


Patent
Nb Health Laboratory Co. and PharmaDesign Inc. | Date: 2011-08-08

There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1 and casein kinase 1. In addition, the present inhibitor inhibits casein kinase 1 and casein kinase 1, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1 or casein kinase 1 is associated. There is further provided a pharmaceutical agent useful for the treatment of particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1 and casein kinase 1 comprising, as an act ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom (which may be any one of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom).


Patent
Kumamoto University and Nb Health Laboratory Co. | Date: 2011-09-28

It is an object of the present invention to provide an antibody that binds to a human PGE

Discover hidden collaborations